
China's second export
China's impact on Europe will often be described through individual successes: a medicine licensed by a Western company, a European approval, a major congress presentation or a domestic biotech securing an international partner. These milestones matter. But China's second oncology export may be more consequential: speed from molecule to trial, from trial to approval, and from approval into a market containing several active competitors. That speed will put pressure on European development timelines. It will force companies to monitor indications as ecosystems rather than lists of isolated competitors. It will make access, affordability and sequencing more important sources of differentiation. And it will expose the cost of waiting until a China-only Phase III study is complete before asking whether the evidence can travel.
